News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.


Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act)

Supervisory Board of Epigenomics AG appoints Gregory Hamilton as Chief Executive Officer (CEO)

Berlin, Germany, June 30, 2016 – The Supervisory Board of Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50) has today appointed Gregory Hamilton as Chief Executive Officer with effect from July 1, 2016. Mr. Hamilton, who has held senior management positions in the U.S. molecular diagnostics industry, will succeed Dr. Thomas Taapken who has today resigned from his office.

Mr. Hamilton, (46), has over 20 years of management experience in molecular diagnostics, manufacturing and professional service industries. Prior to joining Epigenomics, Mr. Hamilton was Chief Executive Officer & Director of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc. and Vice President of Operations at Hologic Inc. He has been responsible for multiple FDA-cleared products including a Human Papilloma Virus (HPV) High Risk Screening assay and the first ever cleared HPV genotyping assay. Mr. Hamilton received his MBA from the University of Chicago and his Bachelor of Science in Finance from Purdue University.

Dr. Thomas Taapken, who has served in the dual role of CEO and CFO since 2012, will leave the company with effect of today. The Supervisory Board expressed its great appreciation for Dr. Taapken’s outstanding contributions to the development of the company. The Supervisory Board wishes Dr. Taapken all the best for the future.

The vacant CFO position will be filled shortly.

– end of ad-hoc-


Contact Epigenomics AG

Peter Vogt

VP Corporate Communications & Investor Relations

Geneststraße 5

10829 Berlin

Phone +49 (0) 30 24345 386


Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.